1Wk·

I would be delighted

if the analyst is right and $RKLB (+0.26%) and the C/R ratio improves and I can get in at a lower price despite my deep sleep phase in recent months.


Investing.com - Craig-Hallum initiated coverage of Rocket Lab USA (NASDAQ:RKLB) with a "hold" rating and a price target of $51.00. The stock, which has risen by 778% in the past year and is currently trading at USD 45.33, has shown remarkable momentum with a gain of 64% in the last six months.

Although the analyst firm acknowledged Rocket Lab's successes and development, it considers the share to be "perfectly priced in" with regard to the upcoming launch schedule for the Neutron rocket. This plan envisages one, three and five successful launches in 2025, 2026 and 2027 respectively. An analysis by InvestingPro supports this assessment and shows that the share is currently trading above its fair value, which is also reflected in a high sales multiple and volatile price movements (beta: 2.16).

Craig-Hallum noted that perfect execution in the development of new rocket platforms is historically "virtually unheard of", with delays or failures often leading to significantly greater schedule setbacks than originally anticipated.

The analyst firm also highlighted competitive risks, particularly from SpaceX's Falcon 9 and potentially the Starship in the future. The latter, should SpaceX achieve its rapid reusability goals, could "change the cost paradigm for the entire industry again".

At 28 times estimated revenue for the 2026 financial year, Rocket Lab is trading at a significant premium to other NewSpace companies, which are trading at 7 times revenue. While Craig-Hallum believes this premium is justified given the company's "tremendous track record of execution", he expects "a better entry point with a more favorable risk/reward ratio at a later date".

In other recent news, Rocket Lab USA has been the focus of several notable developments. For example, Citi analyst Jason Gursky raised the price target for the stock from USD 33 to USD 50 and maintained a "buy" rating. This adjustment is based on Rocket Lab's progress in the development of the Neutron rocket and the expected growth in the satellite systems business. Gursky's re-rating takes into account the company's potential revenues in 2029, which are estimated at around USD 2.6 billion.

Rocket Lab has also awarded a contract to Bollinger Shipyards to build an ocean-going landing platform for its reusable Neutron rocket. The platform, named "Return On Investment", is scheduled for delivery by early 2026 and will be equipped with advanced support equipment for rocket landings at sea. Meanwhile, Cantor Fitzgerald has reiterated its Overweight rating and $35 price target on Rocket Lab following the company's recent successful satellite launches. These developments underscore Rocket Lab's continued efforts to expand its capabilities and market reach in the aerospace sector.

previw image
17
17 Comments

Which brand are you planning to start with?
2
profile image
@ElbeInvestments definitely under 40$, better under 35$
2
profile image
Earnings are on August 7, so who knows whether it will really drop sharply after that
2
I don't see how Falcon 9 and Starship should be competitors, as they are completely different in size and business area.
1
profile image
@Spinat I don't care where the setback comes from. The main thing is that I can get in cheaper. But I see the biggest risk in a delay in the development process. The targets are ambitious and so is the share price.
1
profile image
@Spinat Of course, the Falcon 9 is a competitor, they do about 17-20 tons, the Neutron should do about 13 tons. Both are in the classic "medium lift" segment
1
Wiki writes 8 tons for neutron, but I'm really no expert here.
PS, I have found 13.
I'm also still waiting for around €35 and at €30 I'll really add to it.
I find the market very exciting and can imagine another tenbagger in the long term. I'm curious to see where they will be in 2035-2040.
1
profile image
Purely Chris - in my opinion, the few euro price correction is irrelevant over the next few years :)
1
profile image
@Tobiwankenobi500 but I'm no longer 30 and won't be holding them until 2035 or 2040 😂
1
profile image
1
profile image
@Tobiwankenobi500 that would be nice! 😊
profile image
Hello Chris,
Have you parted ways with Mainstreet Capital? May I ask why? I am also thinking about realizing my profits, but I see that there is still a lot of buying going on at every price. So I'm afraid that I might be in a hurry to act. I'm currently up just under 14%.
1
profile image
@Iwamoto Hello Kate, what makes you think I've split up? I haven't. On the contrary, I keep adding to my savings plan.
1
profile image
@Multibagger Didn't find them during the weekly check 🤪 of your depot. On the second run, now I've seen them. May I ask what makes you so positive about BioNTech?
1
profile image
@Iwamoto So, so, you're controlling me. Well, we're off to a good start😂

$BNTX is my absolute favorite in the biotech sector, big pipeline, well capitalized, have shown they understand MRNA, and I'm a big fan of prevention through vaccination rather than medication after disease outbreak. I see $BNTX at $500 by 2030 if only 2 or 3 of the compounds work. And I don't think $GSK would have poured so much capital into it if they hadn't seen encouraging interim trial results.
Of course there are risks, but in my view they are not as high as with the many biotech penny stocks that are just burning money.
1
Thanks for the info Chris, I'm also wondering when the right time is. I'm thinking about getting in now and buying in if there is another drop. I am convinced of the company in the long term.
Join the conversation